NLRP3 and cancer: Hence, these findings indicate that blocking NLRP3 inflammasome activation with MCC950 may delay tumour growth and enhance checkpoint inhibitors responsiveness through the upregulation of effector antitumour T cells [169], clearly highlighting the usefulness of MCC950 as a potent therapeutic in inflammasome-associated cancers.